Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT04574284
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
- Conditions
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT04569838
- Locations
- 🇨🇳
Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 528
- Registration Number
- NCT04523272
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04523285
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT04481607
- Locations
- 🇨🇳
The Affiliated Hosptial of Xuzhou Medical University, Xuzhou, Jiangsu, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Tianjing Medical University Cancer Institute&Hospital, Tianjin, Tianjin, China
A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 369
- Registration Number
- NCT04439890
- Locations
- 🇨🇳
Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT04412577
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT04412564
- Locations
- 🇨🇳
Shanghai Jiaotong University Affiliated Chest Hospital, Shanghai, Shanghai, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳The Second Hospital of Anhui medical University, Hefei, Anhui, China
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT04408079
- Locations
- 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 332
- Registration Number
- NCT04405505
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Chinese Academy of Medical Sciencesand Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China